Why Amgen Stock Popped by 4% Today
Following quite encouraging news from the laboratory on Monday, (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher on the back of both that sentiment and a pair of optimistic analyst takes on the latest development. With that share price rise, Amgen easily beat the S 500 index, which slid by 0.1%.
That news concerned Amgen's investigational stomach cancer drug, bemarituzumab. The company announced Monday that, in combination with chemotherapy, the treatment met its primary endpoint of of overall survival for the patients tested in a phase 3 clinical trial. It compared favorably to the results of patients only taking a placebo and receiving chemotherapy.
Image source: Getty Images.
Source Fool.com
Amgen Inc. Aktie
Amgen Inc. wird von der Community favorisiert: Deutlich mehr Buy- als Sell-Einschätzungen.
Trotz eines niedrigeren Kursziels von 340 € für Amgen Inc. als der aktuelle Kurs von 358.95 €, zeigt sich ein negatives Potenzial von -5.28%.
